View results from the DEFINITIVE LE study for TurboHawk™ and SilverHawk™ directional atherectomy devices.
The DEFINITIVE LE study is one of the largest multinational, multicenter PAD device studies to date, enrolling 800 patients from 47 sites in the United States and Europe. It provides insight into the clinical utility of directional atherectomy with the TurboHawk™ and SilverHawk™ directional atherectomy devices in a broad range of patients, including diabetics, non-diabetics, claudicants, and those with critical limb ischemia (CLI).
Read more about the DEFINITIVE LE clinical study in published, peer-reviewed journals:
Download these clinical paper reviews and learn more about DEFINITIVE LE results overall.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
